This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Relevant link 3

The GLP-1 Academy is a learning platform designed to keep healthcare professionals informed about developments in GLP-1 science and GLP-1 RA therapy.

1.

RYBELSUS® [summary of product characteristics].

2.

Rosenstockj, All ison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial.JAMA 2019; Apr 16;321(15):1466-1480.

3.

Rodbard HW, Rosenstockj, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care 2019; 42 (12): 2272-2281.

4.

Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 2019; 394 (10192): 39-50.

5.

Aroda VR, Faurby M, Lop havenS, Noone J, Wolden ML, Lingvay I. Insights into the early use of oral semaglutide in routine clinical practice: the IGNITE study. Diabetes Obes Metab 2021; 23(9): 2177-2182.

6.

Gibbons C, Blundell J. Tetens Hoff S, Dahl K, Bauer R, Baekdal T. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes, Obesity and Metabolism 2020; 23(2): 581-588.